重组ADAMTS13治疗先天性血栓性血小板减少性紫癜:随机3期试验最终分析
这项开放标签交叉3期试验最终分析纳入48例先天性TTP患者,随机分配至重组ADAMTS13或血浆为基础治疗 prophylaxis。结果显示重组ADAMTS13组无急性TTP事件,治疗相关不良事件发生率更低,ADAMTS13活性提升约6倍,支持其持续临床获益。
要点
- 重组ADAMTS13预防组无急性TTP事件,血浆治疗组1例。
- 治疗相关不良事件发生率重组ADAMTS13组4.3%,血浆组45.8%。
- 重组ADAMTS13组ADAMTS13活性提升约6倍,且≥10%持续时间更长。
核心结论
- 更长期随访结果与期中分析一致,支持重组ADAMTS13预防治疗在先天性TTP中的持续临床获益。
研究设计与样本
- 3期开放标签交叉试验(NCT03393975),48例3-68岁先天性TTP患者随机1:1分配至两个6个月预防期,分别接受重组ADAMTS13(40 IU/kg)或血浆为基础治疗,随后交换治疗,之后所有患者接受6个月重组ADAMTS13。
主要发现
- 重组ADAMTS13预防期间无急性TTP事件,血浆为基础治疗预防期间1例发生急性事件(平均年化事件率[AER] 0.04)。
- 亚急性TTP事件的模型平均AER在重组ADAMTS13组为0.04,血浆为基础治疗组为0.26。
- 血小板减少是最常见TTP表现(模型平均AER:重组ADAMTS13组0.91,血浆为基础治疗组1.62)。
- 治疗相关不良事件发生率重组ADAMTS13组4.3%,血浆为基础治疗组45.8%;无严重不良事件被认为与重组ADAMTS13相关,1例严重不良事件(发热)被认为与血浆为基础治疗相关。
- 未检测到ADAMTS13中和抗体;重组ADAMTS13组治疗满意度更高(9项药物治疗满意度问卷评估),ADAMTS13活性提升约6倍且≥10%持续时间更长。
临床怎么用
- 对于先天性TTP患者,重组ADAMTS13预防治疗可考虑用于减少急性事件和治疗相关不良事件,并提高治疗满意度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recombinant ADAMTS13 (rADAMTS13) was approved for prophylactic or on-demand ADAMTS13 replacement therapy for congenital thrombotic thrombocytopenic purpura (TTP) based on data from a preplanned interim analysis of a phase 3, open-label, crossover trial (NCT03393975). Here, we report results from the final analysis with 48 participants (3-68 years old) randomized 1:1 to two 6-month periods of prophylaxis with rADAMTS13 (40 IU/kg) or plasma-based therapy (PBT), followed by the alternate treatment at the same frequency; thereafter, all participants received 6 months of rADAMTS13. The primary outcome was acute TTP events. No participants experienced an acute event during rADAMTS13 prophylaxis, whereas 1 experienced an acute event during PBT prophylaxis (mean annualized event rate [AER], 0.04). A lower model-based mean AER of subacute TTP events was observed during rADAMTS13 prophylaxis (0.04) versus PBT (0.26). Thrombocytopenia was the most frequent TTP manifestation (model-based mean AER, 0.91 with rADAMTS13 and 1.62 with PBT). Treatment-related adverse events (AEs) occurred in 4.3% of participants with rADAMTS13 and in 45.8% with PBT. No serious AEs were considered related to rADAMTS13, whereas 1 serious AE (pyrexia) was considered related to PBT. No ADAMTS13-neutralizing antibodies were detected. Greater treatment satisfaction was reported for rADAMTS13 prophylaxis versus PBT (assessed using the 9-item Treatment Satisfaction Questionnaire for Medication). A ~6-fold increase in ADAMTS13 activity and prolonged time with ADAMTS13 activity of ≥10% was noted in participants receiving rADAMTS13 versus PBT. Consistent with the interim analysis, results with a longer follow-up support the continued clinical benefit of rADAMTS13 prophylaxis in congenital TTP.
引用
- Scully M, Matsumoto M, Cataland SR, et al. Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura: final analysis from a randomized phase 3 trial. Blood. 2026. PMID: 42728013. doi:10.1182/blood.2026034361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。